By Matthew Perrone

U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.

RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.

The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.

“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.

Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.

AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.

Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.

FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.

Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.

A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.

In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.

After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Share:
More In Science
Runwise Raises $11 Million to Reverse Climate Change by Updating Buildings
Commercial and residential buildings account for 13% of carbon emissions in the U.S., according to the EPA, and one company says it has a solution. Runwise says it has updated the boiler and heating systems of thousands of buildings, and that its technology not only lowers carbon output but also saves landlords money. Lee Hoffman, Co-Founder and COO of Runwise, joined Cheddar Climate to discuss.
Plastic Pollution in Oceans Presents Growing Threat to Marine Life
Jo Ruxton, Founder of Ocean Generation, joins Cheddar Climate, where she explains the threat that plastic pollution poses to marine life, but elaborates on why we shouldn't be looking to ban plastic entirely. Ruxton also discusses her biggest takeaways while producing the film ‘A Plastic Ocean.'
As Biden Says Agenda Can be Passed in 'Chunks,' Will Senate Dems Rally Around Climate Provisions?
President Joe Biden's Build Back Better deal seems all but finished after months of Democratic infighting and the Senate's deadlock over certain provisions. But Biden mentioned during a press conference marking his first year in office that 'chunks' of the bill could be passed. Is that enough motivation to force Democrats to rally around certain parts of the bill - especially those that focus on climate and green energy? Andrew Freedman, Energy and Climate Reporter at Axios, joins Cheddar Climate to discuss whether Senate Democrats will be able to rally around climate provisions, if the idea of passing Build Back Better in 'chunks' is doable, and more.
Acid Rain And The Sneaky Policy That "Solved" It
Anyone who remembers the 70s and 80s will probably remember acid rain. Industrial emissions acidified precipitation around the globe, which killed forests and crops, rendered lakes inhospitable, corroded buildings, and exacerbated human health problems. But anyone who follows environmental news will be surprised to learn this: we solved it! Countries came together to limit acid rain-causing emissions, eliminating the problem altogether. …kind of. Acidic precipitation may not be a thing of the past after all.
Breakthroughs in MDMA-Assisted Therapy to Treat PTSD; Music, Artificial Intelligence, and Psychedelics Combining to Treat Depression
On this episode of Cheddar Reveals, Natalie Ginsberg, Global Impact Officer, MAPS, discusses the MAPS organization and its current initiatives and their work to get FDA approval for MDMA to treat PTSD; Kelsey Ramsden, Co-Founder, President & CEO, Mind Cure Health, breaks down what 'psychedelic therapy' could look like once it's legalized and how Mind Cure Health is using AI to help treat everything from addiction to depression; Cheddar gets a look at Curiosity Stream's 'Pain, Pus and Poison.'
Load More